Mozobil in Stem Cell Transplantation

A Panel Discussion Among Four Clinicians and Researchers

May 2007

Study Description and Objectives

§    Assess awareness and general impressions of Genzyme’s Mozobil

·     Level of excitement surrounding this agent

·     Explore validity, viability, and appeal of Mozobil’s mechanism of action as an inhibitor of the CXCR4 receptor

o        Discussion of its profile, potential strengths, weaknesses, concerns, etc.

·     Likelihood of approval

·     Clinical and commercial potential

§    Determine Mozobil’s anticipated role in treatment algorithms for autologous peripheral blood stem cell transplant patients, particularly those with multiple myeloma and NHL

·     Candidate patient characteristics (patient age, stage of malignancy, prior treatment)

·     Could it become standard of care?

§    Compare Mozobil with and differentiate it from other investigational agents

§    Discuss other possible areas of investigation for Mozobil

·     Other malignancies – leukemias

·     Revascularization

·     Any hope for HIV?

Companies and Products Mentioned in This Report

Inclusion Criteria and Panelist Demographics

 Hospitals Represented 

Reports become free one year after the publication date.